TLPPF
Telix Pharmaceuticals Limited
Price Chart
Latest Quote
$9.50
+0.74 (+8.45%)
Current Price
| Previous Close | $8.76 |
| Open | $9.00 |
| Day High | $9.00 |
| Day Low | $9.00 |
| Volume | 200 |
Stock Information
| Shares Outstanding | 338.78M |
| Total Debt | $467.11M |
| Cash Equivalents | $141.87M |
| Revenue | $803.79M |
| Net Income | $-7.12M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.22B |
| EPS (TTM) | $-0.02 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.54B |
| Sales | $803.79M |
| Income | $-7.12M |
| Book/sh | $1.23 |
| Cash/sh | $0.42 |
| Employees | 1K |
Financial Ratios
| Quick Ratio | 1.21 |
| Current Ratio | 1.43 |
| Debt/Eq | 112.45 |
Returns & Margins
| ROA | 1.15% |
| ROE | -1.86% |
| Gross Margin | 47.50% |
| Operating Margin | 1.94% |
| Profit Margin | -0.89% |
Ownership
| Insider Ownership | 17.26% |
| Institutional Ownership | 30.22% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 4.00 |
| P/B | 7.75 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $9.88 |
| SMA50 | $9.93 |
| SMA200 | $9.08 |
| RSI | 32.61 |
| ATR | 0.1936 |
| Shares Float | 272.74M |
| Volatility | 0.59 |
| Rel Volume | 0.19 |
Performance History
| Week | +0.00% |
| Month | -9.52% |
| Quarter | +35.71% |
| 6 Months | +3.71% |
| YTD | +24.84% |
| Year | -42.53% |
| 3 Years | +23.38% |
| 5 Years | +179.41% |
| 10 Years | +771.56% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-04 | $9.50 | 100 |
| 2026-06-03 | $8.76 | 440 |
| 2026-06-02 | $9.00 | 200 |
| 2026-06-01 | $9.20 | 1,107 |
| 2026-05-29 | $9.50 | 0 |
| 2026-05-28 | $9.50 | 900 |
| 2026-05-27 | $9.75 | 1,235 |
| 2026-05-26 | $9.75 | 0 |
| 2026-05-22 | $9.75 | 0 |
| 2026-05-21 | $9.75 | 1,245 |
| 2026-05-20 | $9.75 | 813 |
| 2026-05-19 | $9.75 | 0 |
| 2026-05-18 | $9.75 | 155 |
| 2026-05-15 | $9.74 | 130 |
| 2026-05-14 | $10.30 | 312 |
| 2026-05-13 | $10.80 | 200 |
| 2026-05-12 | $10.26 | 3,312 |
| 2026-05-11 | $10.65 | 650 |
| 2026-05-08 | $11.06 | 0 |
| 2026-05-07 | $11.06 | 0 |
| 2026-05-06 | $11.06 | 2,350 |
| 2026-05-05 | $10.50 | 0 |
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
đ° Latest News
ASX Growth Companies With Insider Ownership Up To 20%
Simply Wall St. âĸ 2026-06-04T19:38:32Z
Is Telix (ASX:TLX) Quietly Assembling a Connected Oncology Platform That Reshapes Its Moat?
Simply Wall St. âĸ 2026-05-28T21:10:43Z
Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of Shares
Simply Wall St. âĸ 2026-05-01T20:50:51Z
How TLX597-Tx Phase 2 Dosimetry Data Will Impact Telix Pharmaceuticals (ASX:TLX) Investors
Simply Wall St. âĸ 2026-04-30T06:04:23Z
Telix Pharmaceuticals Webinar Highlights Next-Gen PSMA Therapy, OPTIMAL-PSMA Enrollment Nears End
MarketBeat âĸ 2026-04-30T01:36:59Z
Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock.
Barrons.com âĸ 2026-04-29T20:43:00Z
Telix Pharmaceuticals (TLX): How Are Its Clinical Programs Doing?
Insider Monkey âĸ 2026-04-28T17:30:23Z
ASX Growth Leaders With High Insider Ownership April 2026
Simply Wall St. âĸ 2026-04-26T19:38:15Z
Regeneron Broadens Dupixent Use And Enters Radiopharmaceuticals With Telix
Simply Wall St. âĸ 2026-04-20T06:03:31Z
Regeneron Pharmaceuticals (REGN) Announces Collaboration With Telix Pharmaceuticals Limited
Insider Monkey âĸ 2026-04-20T00:07:19Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $170,088,175 | $128,191,555 | $44,335,143 | $1,847,073 |
| Cost Of Revenue | $170,088,175 | $128,191,555 | $44,335,143 | $1,847,073 |
| Total Revenue | $487,020,570 | $342,385,780 | $108,913,289 | $3,550,613 |
| Operating Revenue | $487,020,570 | $342,385,780 | $108,913,289 | $3,550,613 |
| Expenses | ||||
| Interest Expense | $22,691,150 | $9,237,079 | $4,496,782 | $3,782,585 |
| Total Expenses | $436,370,137 | $307,048,740 | $159,388,819 | $75,171,804 |
| Rent Expense Supplemental | $2,642,772 | $2,323,918 | $1,426,589 | $1,271,494 |
| Other Income Expense | $420,356 | $-24,545,232 | $-12,064,438 | $17,073,825 |
| Other Non Operating Income Expenses | $274,848 | $14,307 | $61,907 | $15,842,926 |
| Net Non Operating Interest Income Expense | $-16,213,561 | $-8,683,181 | $-4,552,567 | $-3,782,585 |
| Total Other Finance Cost | $276,714 | $140,348 | $56,465 | - |
| Interest Expense Non Operating | $22,691,150 | $9,237,079 | $4,496,782 | $3,782,585 |
| Operating Expense | $266,281,962 | $178,857,186 | $115,053,676 | $73,324,731 |
| Other Operating Expenses | $453,935 | $-117,865 | $691,865 | $15,245,600 |
| Selling And Marketing Expense | $71,632,176 | $42,688,959 | $29,239,289 | $4,270,450 |
| General And Administrative Expense | $73,164,984 | $48,713,704 | $30,231,166 | $25,313,161 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $31,041,066 | $3,550,260 | $-70,804,931 | $-58,362,571 |
| Net Interest Income | $-16,213,561 | $-8,683,181 | $-4,552,567 | $-3,782,585 |
| Interest Income | $6,754,303 | $694,246 | $680 | - |
| Normalized Income | $30,911,488 | $20,741,937 | $-62,316,489 | $-59,224,200 |
| Net Income From Continuing And Discontinued Operation | $31,041,066 | $3,550,260 | $-70,804,931 | $-58,362,571 |
| Total Operating Income As Reported | $51,070,789 | $10,791,808 | $-62,539,968 | - |
| Net Income Common Stockholders | $31,041,066 | $3,550,260 | $-70,804,931 | $-58,362,571 |
| Net Income | $31,041,066 | $3,550,260 | $-70,804,931 | $-58,362,571 |
| Net Income Including Noncontrolling Interests | $31,041,066 | $3,550,260 | $-70,804,931 | $-58,362,571 |
| Net Income Continuous Operations | $31,041,066 | $3,550,260 | $-70,804,931 | $-58,362,571 |
| Pretax Income | $34,857,228 | $2,103,176 | $-67,092,534 | $-58,329,950 |
| Special Income Charges | $-11,485,797 | $-23,899,358 | $-11,365,770 | - |
| Interest Income Non Operating | $6,754,303 | $694,246 | $680 | - |
| Operating Income | $50,650,433 | $35,337,040 | $-50,475,530 | $-71,621,191 |
| Gross Profit | $316,932,395 | $214,194,225 | $64,578,146 | $1,703,540 |
| Depreciation Amortization Depletion Income Statement | - | $6,743,000 | $3,659,333 | $3,750,689 |
| Depreciation And Amortization In Income Statement | - | $6,743,000 | $3,659,333 | $3,750,689 |
| Amortization Of Intangibles Income Statement | - | $4,344,000 | $2,787,869 | $3,029,402 |
| Depreciation Income Statement | - | $2,399,000 | $871,464 | $721,286 |
| Per Share | ||||
| Diluted EPS | $0.09 | $0.01 | $-0.23 | $-0.21 |
| Basic EPS | $0.09 | $0.01 | $-0.23 | $-0.21 |
| Other | ||||
| Tax Effect Of Unusual Items | $15,930 | $-7,367,862 | $-3,637,904 | $369,270 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $57,402,870 | $35,899,794 | $-50,469,407 | $-52,027,576 |
| Total Unusual Items | $145,508 | $-24,559,539 | $-12,126,345 | $1,230,899 |
| Total Unusual Items Excluding Goodwill | $145,508 | $-24,559,539 | $-12,126,345 | $1,230,899 |
| EBITDA (Bullshit earnings) | $57,548,378 | $11,340,255 | $-62,595,752 | $-50,796,677 |
| EBIT | $57,548,378 | $11,340,255 | $-62,595,752 | $-54,547,366 |
| Diluted Average Shares | $345,188,000 | $319,181,000 | $310,644,169 | $282,206,000 |
| Basic Average Shares | $331,226,000 | $319,181,000 | $310,644,169 | $282,206,000 |
| Diluted NI Availto Com Stockholders | $31,041,066 | $3,550,260 | $-70,804,931 | - |
| Tax Provision | $3,816,163 | $-1,447,083 | $3,712,396 | $32,621 |
| Impairment Of Capital Assets | $-477,564 | $547,766 | $0 | - |
| Restructuring And Mergern Acquisition | $11,963,362 | $23,351,592 | $11,365,770 | - |
| Gain On Sale Of Security | $11,631,305 | $-660,181 | $-760,575 | $1,230,899 |
| Research And Development | $121,030,868 | $87,572,388 | $54,891,356 | $24,744,831 |
| Selling General And Administration | $144,797,159 | $91,402,663 | $59,470,455 | $29,583,611 |
| Other Gand A | $70,522,212 | $46,389,786 | $28,804,577 | $2,218,952 |
| Rent And Landing Fees | $2,642,772 | $2,323,918 | $1,426,589 | $1,271,494 |
| Reconciled Depreciation | - | $6,743,000 | $3,659,333 | $3,750,689 |
| Amortization | - | $4,344,000 | $2,787,869 | $3,029,402 |
| Salaries And Wages | - | - | $43,869,138 | $21,822,716 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $94,567,083 | $26,739,702 | $14,301,944 | $-38,834,198 |
| Total Assets | $942,960,278 | $276,579,596 | $173,716,614 | $79,604,634 |
| Total Non Current Assets | $371,770,844 | $118,174,386 | $55,866,226 | $45,140,198 |
| Other Non Current Assets | $46,377,226 | $399,242 | - | - |
| Non Current Deferred Assets | $29,062,407 | $13,933,968 | $2,701,471 | - |
| Non Current Deferred Taxes Assets | $29,062,407 | $13,933,968 | $2,701,471 | - |
| Investmentin Financial Assets | $0 | $1,882,435 | - | - |
| Goodwill And Other Intangible Assets | $258,764,053 | $74,713,513 | $40,126,808 | $40,398,556 |
| Other Intangible Assets | $192,447,891 | $71,411,247 | $36,372,233 | $37,428,596 |
| Current Assets | $571,189,434 | $158,405,211 | $117,850,388 | $34,464,436 |
| Prepaid Assets | $6,889,862 | $8,463,121 | $1,706,192 | $874,967 |
| Inventory | $23,719,033 | $11,793,321 | $5,766,902 | $2,503,842 |
| Receivables | $98,867,028 | $54,187,276 | $26,772,521 | $14,077,768 |
| Other Receivables | $1,616,755 | $1,609,914 | - | $13,548,584 |
| Taxes Receivable | $10,539,374 | $8,444,726 | - | - |
| Accounts Receivable | $86,710,899 | $44,132,636 | $26,772,521 | $529,185 |
| Allowance For Doubtful Accounts Receivable | $-131,206 | $-363,133 | - | - |
| Gross Accounts Receivable | $86,842,105 | $44,495,769 | $26,772,521 | $529,185 |
| Cash Cash Equivalents And Short Term Investments | $441,713,511 | $83,961,493 | $79,138,604 | $15,974,860 |
| Cash And Cash Equivalents | $441,713,511 | $83,961,493 | $79,138,604 | $15,974,860 |
| Non Current Accounts Receivable | - | $586,000 | $222,458 | $153,681 |
| Other Current Assets | - | $7,102,000 | $4,466,169 | $1,032,998 |
| Cash Financial | - | $123,237,000 | $79,138,604 | $15,974,860 |
| Debt | ||||
| Total Debt | $361,561,039 | $11,885,296 | $7,106,413 | $1,840,549 |
| Long Term Debt And Capital Lease Obligation | $348,200,428 | $10,823,148 | $6,670,340 | $1,382,405 |
| Long Term Debt | $343,138,121 | $5,592,800 | $2,253,153 | - |
| Current Debt And Capital Lease Obligation | $13,360,611 | $1,062,148 | $436,072 | $458,144 |
| Current Debt | $11,808,527 | $656,774 | - | $13,773 |
| Other Current Borrowings | $11,808,527 | $656,774 | - | $13,773 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $589,629,141 | $175,126,381 | $119,287,862 | $78,040,276 |
| Total Non Current Liabilities Net Minority Interest | $383,858,571 | $62,668,111 | $61,084,126 | $50,506,713 |
| Other Non Current Liabilities | $18,907,323 | $37,881,018 | $15,321,714 | $16,713,544 |
| Non Current Deferred Liabilities | $7,877,947 | $8,285,983 | - | - |
| Non Current Deferred Taxes Liabilities | $5,833,375 | $0 | - | - |
| Current Liabilities | $205,770,570 | $112,458,270 | $58,203,736 | $27,533,563 |
| Other Current Liabilities | $53,421,301 | $25,312,377 | $3,360,681 | $4,453,127 |
| Current Deferred Liabilities | $6,994,329 | $7,490,905 | $4,979,795 | - |
| Payables And Accrued Expenses | $117,217,192 | $68,721,471 | $33,687,770 | $13,802,302 |
| Payables | $84,036,414 | $40,107,509 | $33,687,770 | $13,802,302 |
| Other Payable | $11,111,457 | $4,679,175 | $22,254,650 | $5,187,462 |
| Total Tax Payable | $30,206,571 | $13,056,453 | - | - |
| Accounts Payable | $42,718,386 | $22,371,881 | $11,433,120 | $8,614,840 |
| Current Deferred Taxes Liabilities | - | $11,508,000 | $4,979,795 | - |
| Equity | ||||
| Common Stock Equity | $353,331,136 | $101,453,215 | $54,428,752 | $1,564,358 |
| Total Equity Gross Minority Interest | $353,331,136 | $101,453,215 | $54,428,752 | $1,564,358 |
| Stockholders Equity | $353,331,136 | $101,453,215 | $54,428,752 | $1,564,358 |
| Gains Losses Not Affecting Retained Earnings | $114,664,586 | $-22,954,394 | $-12,347,443 | $3,471,598 |
| Other Equity Adjustments | $114,664,586 | $-22,954,394 | $-11,965,114 | $4,307,420 |
| Retained Earnings | $-132,425,878 | $-179,635,231 | $-185,596,011 | $-125,751,008 |
| Long Term Equity Investment | $3,788,802 | $6,470,316 | - | - |
| Investments In Other Ventures Under Equity Method | $3,788,802 | $6,470,316 | - | - |
| Other | ||||
| Ordinary Shares Number | $334,724,485 | $323,727,000 | $316,343,000 | $285,073,000 |
| Share Issued | $334,724,485 | $323,727,000 | $316,343,000 | $285,073,000 |
| Tangible Book Value | $94,567,083 | $26,739,702 | $14,301,944 | $-38,834,198 |
| Invested Capital | $708,277,783 | $107,702,789 | $56,681,905 | $1,578,131 |
| Working Capital | $365,418,864 | $45,946,940 | $59,646,652 | $6,930,873 |
| Capital Lease Obligations | $6,614,392 | $5,635,722 | $4,853,259 | $1,826,775 |
| Total Capitalization | $696,469,257 | $107,046,015 | $56,681,905 | $1,564,358 |
| Additional Paid In Capital | $371,092,429 | $304,042,840 | - | - |
| Capital Stock | $0 | $0 | $252,372,206 | $123,843,767 |
| Common Stock | $0 | $0 | $252,372,206 | $123,843,767 |
| Employee Benefits | $309,049 | $224,829 | $146,264 | $95,688 |
| Non Current Deferred Revenue | $2,044,573 | $8,285,983 | - | - |
| Long Term Capital Lease Obligation | $5,062,307 | $5,230,348 | $4,417,187 | $1,382,405 |
| Long Term Provisions | $8,563,824 | $5,453,133 | $38,945,807 | $32,315,075 |
| Current Deferred Revenue | $6,994,329 | $7,490,905 | - | - |
| Current Capital Lease Obligation | $1,552,084 | $405,374 | $436,072 | $444,370 |
| Pensionand Other Post Retirement Benefit Plans Current | $14,198,836 | $9,478,260 | $5,136,944 | $3,453,475 |
| Current Provisions | $578,301 | $393,111 | $10,602,474 | $5,366,515 |
| Current Accrued Expenses | $33,180,778 | $28,613,961 | - | - |
| Investments And Advances | $3,788,802 | $8,352,750 | - | - |
| Investmentsin Associatesat Cost | $2,696,000 | $0 | - | - |
| Goodwill | $66,316,163 | $3,302,266 | $3,754,575 | $2,969,960 |
| Net PPE | $33,778,355 | $20,774,912 | $12,815,489 | $4,587,961 |
| Accumulated Depreciation | $-5,775,545 | $-3,962,447 | $-2,296,012 | $-1,517,963 |
| Gross PPE | $39,553,900 | $24,737,358 | $15,111,501 | $6,105,924 |
| Leases | $8,912,670 | $7,403,698 | $1,048,342 | $272,566 |
| Machinery Furniture Equipment | $14,319,471 | $3,195,302 | $1,159,231 | $1,338,185 |
| Land And Improvements | $16,321,759 | $14,138,359 | $9,830,000 | $2,352,000 |
| Properties | $0 | $0 | $6,687,348 | $1,704,990 |
| Inventories Adjustments Allowances | $-2,589,295 | $0 | - | - |
| Finished Goods | $8,724,256 | $2,486,067 | $1,552,444 | $123,960 |
| Work In Process | $8,632,226 | $4,061,235 | $2,566,771 | - |
| Raw Materials | $8,951,846 | $5,246,018 | $1,647,686 | $2,379,882 |
| Foreign Currency Translation Adjustments | - | $-68,243,000 | $-382,329 | $-835,822 |
| Non Current Pension And Other Postretirement Benefit Plans | - | $330,000 | $215,000 | $132,000 |
| Other Investments | - | $12,260,000 | - | - |
| Available For Sale Securities | - | $1,882,435 | - | - |
| Other Properties | - | $11,154,000 | $6,216,580 | $2,790,182 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $5,594,593 | $8,918,230 | $-52,948,420 | $-43,978,166 |
| Operating Activities | ||||
| Cash Flowsfromusedin Operating Activities Direct | $26,756,666 | $16,272,193 | $-43,518,783 | $-43,007,510 |
| Other Cash Paymentsfrom Operating Activities | $-22,314,944 | $-11,092,943 | $12,863,790 | $8,788,094 |
| Classesof Cash Receiptsfrom Operating Activities | $446,556,935 | $315,887,940 | $97,285,603 | $3,014,179 |
| Other Cash Receiptsfrom Operating Activities | - | $-16,282,000 | $18,909,000 | $12,123,000 |
| Investing Activities | ||||
| Capital Expenditure | $-21,162,073 | $-7,353,963 | $-9,429,637 | $-970,656 |
| Investing Cash Flow | $-84,054,447 | $-17,365,682 | $-11,563,057 | $-1,976,107 |
| Cash Flow From Continuing Investing Activities | $-84,054,447 | $-17,365,682 | $-11,563,057 | $-1,976,107 |
| Net Other Investing Changes | $-8,991,021 | $-38,153 | $-1,471,489 | $-1,005,451 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $621,207 | $4,532,014 | $123,160,809 | $2,741,613 |
| Financing Cash Flow | $397,300,642 | $6,939,732 | $119,025,266 | $2,063,096 |
| Cash Flow From Continuing Financing Activities | $397,300,642 | $6,939,732 | $119,025,266 | $2,063,096 |
| Net Other Financing Charges | $-9,255,298 | $-2,222,000 | $-5,317,224 | $-596,000 |
| Net Common Stock Issuance | $621,207 | $4,532,014 | $123,160,809 | $2,741,613 |
| Common Stock Issuance | $621,207 | $4,532,014 | $123,160,809 | $2,741,613 |
| Repurchase Of Capital Stock | - | - | $-7,816,000 | - |
| Other | ||||
| Repayment Of Debt | $-1,946,324 | $-1,513,851 | $-868,743 | $-246,470 |
| Issuance Of Debt | $407,881,057 | $3,921,569 | $2,050,424 | - |
| End Cash Position | $441,713,511 | $83,961,493 | $79,138,604 | $15,974,860 |
| Beginning Cash Position | $76,632,300 | $79,255,065 | $14,991,768 | $56,503,175 |
| Effect Of Exchange Rate Changes | $25,078,350 | $-1,139,817 | $203,410 | $2,392,206 |
| Changes In Cash | $340,002,860 | $5,846,244 | $63,943,426 | $-42,920,521 |
| Net Issuance Payments Of Debt | $405,934,733 | $2,407,718 | $1,181,681 | $-678,517 |
| Net Long Term Debt Issuance | $405,934,733 | $2,407,718 | $1,181,681 | $-678,517 |
| Long Term Debt Payments | $-1,946,324 | $-1,513,851 | $-868,743 | $-246,470 |
| Long Term Debt Issuance | $407,881,057 | $3,921,569 | $2,050,424 | - |
| Net Investment Purchase And Sale | $-32,327,629 | $-8,962,515 | $0 | - |
| Purchase Of Investment | $-32,327,629 | $-8,962,515 | $0 | - |
| Net Business Purchase And Sale | $-21,573,724 | $-1,011,051 | $-661,932 | - |
| Purchase Of Business | $-21,573,724 | $-1,011,051 | $-661,932 | - |
| Net Intangibles Purchase And Sale | $-12,256,243 | $-759,651 | $-4,641,686 | - |
| Purchase Of Intangibles | $-12,256,243 | $-759,651 | $-4,641,686 | - |
| Net PPE Purchase And Sale | $-8,905,830 | $-6,594,312 | $-4,787,951 | $-970,656 |
| Purchase Of PPE | $-8,905,830 | $-6,594,312 | $-4,787,951 | $-970,656 |
| Taxes Refund Paid Direct | $-1,746,717 | $-6,985,379 | $11,314,067 | - |
| Interest Received Direct | $6,750,572 | $1,109,839 | $680 | - |
| Interest Paid Direct | $-2,941,250 | $-534,821 | $-277,562 | $-137,008 |
| Classesof Cash Payments | $-423,609,591 | $-300,190,764 | $-140,527,505 | $-45,884,681 |
| Paymentsto Suppliersfor Goodsand Services | $-399,547,931 | $-282,112,442 | $-138,977,781 | $-54,672,775 |
| Receiptsfrom Customers | $446,556,935 | $315,887,940 | $84,421,813 | $3,014,179 |
| Interest Paid Supplemental Data | - | $785,000 | $131,000 | $189,000 |
| Income Tax Paid Supplemental Data | - | $10,253,000 | $2,278,000 | - |
| Common Stock Payments | - | - | $-7,816,000 | - |
Fetched: 2026-02-02